Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and Plasmodium falciparum Clearance in Southern Province, Zambia

Timothy P Finn, Travis R Porter, Hawela Moonga, Kafula Silumbe, Rachel F Daniels, Sarah K Volkman, Joshua O Yukich, Joseph Keating, Adam Bennett, Richard W Steketee, John M Miller, Thomas P Eisele, Timothy P Finn, Travis R Porter, Hawela Moonga, Kafula Silumbe, Rachel F Daniels, Sarah K Volkman, Joshua O Yukich, Joseph Keating, Adam Bennett, Richard W Steketee, John M Miller, Thomas P Eisele

Abstract

Mass drug administration (MDA) with artemisinin combination therapy is a potentially useful tool for malaria elimination programs, but its success depends partly on drug effectiveness and treatment coverage in the targeted population. As part of a cluster-randomized controlled trial in Southern Province, Zambia evaluating the impact of MDA and household focal MDA (fMDA) with dihydroartemisinin-piperaquine (DHAp), sub-studies were conducted investigating population drug adherence rates and effectiveness of DHAp as administered in clearing Plasmodium falciparum infections following household mass administration. Adherence information was reported for 181,534 of 336,821 DHAp (53.9%) treatments administered during four rounds of MDA/fMDA, of which 153,197 (84.4%) reported completing the full course of DHAp. The proportion of participants fully adhering to the treatment regimen differed by MDA modality (MDA versus fMDA), RDT status, and whether the first dose was observed by those administering treatments. Among a subset of participants receiving DHAp and selected for longitudinal follow-up, 58 were positive for asexual-stage P. falciparum infection by microscopy at baseline. None of the 45 participants followed up at days 3 and/or 7 were slide positive for asexual-stage parasitemia. For those with longer term follow-up, one participant was positive 47 days after treatment, and two additional participants were positive after 69 days, although these two were determined to be new infections by genotyping. High completion of a 3-day course of DHAp and parasite clearance in the context of household MDA are promising as Zambia's National Malaria Programme continues to weigh appropriate interventions for malaria elimination.

Conflict of interest statement

Disclaimer: The funding source had no role in the conduct, analysis, or interpretation of results of the study. All authors had full access to all the data in the study.

Figures

Figure 1.
Figure 1.
Clearance microscopy results. Baseline parasite density, timing of follow-up blood slide collection, and microscopy results for participants included in parasite clearance assessment. This figure appears in color at www.ajtmh.org.

References

    1. Zambia Ministry of Health , 2012. National Malaria Control Programme Strategic Plan for FY 2011–2015: Consolidating Malaria Gains for Impact. Lusaka, Zambia: Ministry of Health, National Malaria Control Programme.
    1. Eisele TP, et al. 2015. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials 16: 347.
    1. Yukich JO, et al. 2020. Cost-effectiveness of focal mass drug administration and mass drug administration with dihydroartemisinin-piperaquine for malaria prevention in Southern Province, Zambia: results of a community-randomized control trial. Am J Trop Med Hyg 103 (Suppl 2): 46–53.
    1. Mayxay M, et al. 2006. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People’s Democratic Republic (Laos). Trop Med Int Health 11: 1157–1165.
    1. Ashley EA, et al. 2005. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 41: 425–432.
    1. Trung TN, Tan B, Van Phuc D, Song J, 2009. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med 15: 189–192.
    1. Ogutu BR, et al. 2014. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J 13: 33.
    1. Sylla K, et al. 2013. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. BMC Infect Dis 13: 598.
    1. Song J, et al. 2011. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 10: 231.
    1. Zwang J, et al. 2009. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 4: e6358.
    1. Four Artemisinin-Based Combinations (4ABC) Study Group , 2011. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 8: e1001119.
    1. Sawa P, et al. 2013. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 207: 1637–1645.
    1. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D, 2014. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 1: 1–160.
    1. World Health Organization , 2018. Status Report on Artemisinin Resistance and ACT Efficacy (August 2018). Available at: . Accessed November 29, 2018.
    1. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D, 2014. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS One 9: e84555.
    1. Krentel A, Fischer PU, Weil GJ, 2013. A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis 7: e2447.
    1. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP, 2009. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8: 253.
    1. Gosling RD, Okell L, Mosha J, Chandramohan D, 2011. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect 17: 1617–1623.
    1. Shuford KV, Turner HC, Anderson RM, 2016. Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review. Parasit Vectors 9: 29.
    1. Yeung S, White NJ, 2005. How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health 10: 121–138.
    1. Eisele TP, et al. 2016. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis 214: 1831–1839.
    1. Daniels R, et al. 2008. A general SNP-based molecular barcode for Plasmodium falciparum identification and tracking. Malar J 7: 223.
    1. Tanner M, Lengeler C, Lorenz N, 1993. From the efficacy of disease control tools to community effectiveness. Trans R Soc Trop Med Hyg 87: 518–523.
    1. Littrell M, Miller JM, Ndhlovu M, Hamainza B, Hawela M, Kamuliwo M, Hamer DH, Steketee RW, 2013. Documenting malaria case management coverage in Zambia: a systems effectiveness approach. Malar J 12: 371.
    1. Eisele TP, et al. 2020. Impact of four rounds of mass drug administration with dihydroartemisinin-piperaquine implemented in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 7–18.
    1. Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM, 2014. Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malar J 13: 138.
    1. Nikolov M, Bever CA, Upfill-Brown A, Hamainza B, Miller JM, Eckhoff PA, Wenger EA, Gerardin J, 2016. Malaria elimination campaigns in the Lake Kariba region of Zambia: a spatial dynamical model. PLoS Comput Biol 12: e1005192.
    1. Stepniewska K, White NJ, 2006. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 5: 127.
    1. World Health Organization , 2016. Status Report on Artemisinin and ACT Resistance (October 2016). Available at: . Accessed November 1, 2017.
    1. Muhindo MK, et al. 2014. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J 13: 32.
    1. Juliano JJ, Ariey F, Sem R, Tangpukdee N, Krudsood S, Olson C, Looareesuwan S, Rogers WO, Wongsrichanalai C, Meshnick SR, 2009. Misclassification of drug failures in Plasmodium falciparum clinical trials in southeast Asia. J Infect Dis 200: 624–628.
    1. Juliano JJ, Gadalla N, Sutherland CJ, Meshnick SR, 2010. The perils of PCR: can we accurately ‘correct’ antimalarial trials? Trends Parasitol 26: 119–124.
    1. Budge PJ, Sognikin E, Akosa A, Mathieu EM, Deming M, 2010. Accuracy of coverage survey recall following an integrated mass drug administration for lymphatic filariasis, schistosomiasis, and soil-transmitted helminthiasis. PLoS Negl Trop Dis 10: e0004358.
    1. World Health Organization , 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Available at: . Accessed November 28, 2018.
    1. Chishimba S, et al. 2020. Prevalence of Plasmodium falciparum and non-falciparum infections by photo-induced electron transfer-PCR in a longitudinal cohort of individuals enrolled in a mass drug administration trial in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 82–89.
    1. Kalinowski P, Fidler F, 2010. Interpreting significance: the differences between statistical significance, effect size, and practical importance. Newborn Infant Nurs Rev 10: 50–54.
    1. Kühberger A, Fritz A, Lermer E, Scherndl T, 2015. The significance fallacy in inferential statistics. BMC Res Notes 8: 84.
    1. Yakasai AM, Hamza M, Dalhat MM, Bello M, Gadanya MA, Yaqub ZM, Ibrahim DA, Hassan-Hanga F, 2015. Adherence to artemisinin-based combination therapy for the treatment of uncomplicated malaria: a systematic review and meta-analysis. J Trop Med 2015: 189232.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa